{"schema_version":"secwatch.filing_event.v1","accession":"0001828185-25-000058","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.177474+00:00","generated_at":"2026-05-17T18:12:24.888260+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Barinthus Bio Q2 net loss $21.1M ($0.52/share); cash $87.8M, runway into 2027","bullets":["Cash, cash equivalents & restricted cash $87.8M at June 30, 2025, down $12.8M from Q1.","Q2 net loss $21.1M vs $19.7M in Q1; diluted EPS -$0.52 vs -$0.49.","R&D expenses $8.0M in Q2, down from $8.3M Q1; VTP-1000 celiac trial lead driver.","Phase 1 AVALON SAD final cohort ongoing; topline data expected early Q4 2025.","MAD portion of AVALON started July 2025; data expected mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001828185-25-000058","json":"https://secwatch.observer/filing/0001828185-25-000058.json","markdown":"https://secwatch.observer/filing/0001828185-25-000058.md","text":"https://secwatch.observer/filing/0001828185-25-000058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000058/0001828185-25-000058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000182818525000058/brns-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:12:24.888260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}